Filing Flows › Zevra Therapeutics (ZVRA) › Q3 2026
Zevra Therapeutics (ZVRA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Zevra Therapeutics (ZVRA) reported revenue of $37.8M for the third quarter 2026 (Q3 2026), +45% from a year earlier and -5% from the quarter before. Operating margin was 30.7%, net earnings $19.2M (50.9% of revenue).
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $37.8M | -5% | +45% |
| Operating profit | $11.6M | -31% | +180% |
| Net earnings | $19.2M | +119% | — |
| Operating cash flow | $10.0M | -41% | +113% |
| Free cash flow | $9.8M | -42% | +136% |
What changed
Revenue was $37.8M in Q3 2026, up 45% year over year and down 5% from the previous quarter.
Operating profit was $11.6M, a 30.7% margin (up 14.8 points year over year). Of the extra revenue versus Q3 2025, 64% reached operating profit, above the 16% margin then. Total costs grew 19% against revenue growth of 45%. The fastest-growing cost line was Cost of revenue (+45%). Net earnings were $19.2M. The effective tax rate was 2.6%. Non-operating items added $8.1M, 41% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $10.0M (up 113% year over year), 52% of net earnings. Non-cash charges added back $378K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $12.2M. Capital expenditures of $238K left free cash flow of $9.8M.
Questions
What was Zevra Therapeutics' revenue in the third quarter 2026?
Zevra Therapeutics (ZVRA) reported revenue of $37.8M for the third quarter 2026 (Q3 2026), +45% from a year earlier and -5% from the quarter before.
Was Zevra Therapeutics profitable in the third quarter 2026?
Operating profit was $11.6M (30.7% of revenue) and net earnings $19.2M.
Source: Zevra Therapeutics 10-Q on SEC EDGAR.